Zacks Investment Research on MSN12h
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite SuccessImmunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback